Every year, over 9 million new cases of TB are reported worldwide, with almost 2 million deaths. To make matters worse, the threat of multidrug-resistant bacilli has emerged, making the disease more expensive and difficult to treat.
In 2010, the World Health Organization (WHO) reported an unexpectedly high prevalence of multidrug-resistant tuberculosis with peaks of 25% or more among new cases of TB in some settings. At present, an estimated 5% of the more than 9 million people who develop TB around the world every year are infected with an MDR-TB strain, i.e. a strain that is resistant to (at least) the two most powerful anti-TB drugs currently available, isoniazid and rifampicin.
During a joint press conference at the 20th Annual Congress of the European Respiratory Society, experts in the field of tuberculosis will address current challenges in the management of the disease, such as TB/HIV co-infection and the rise of resistant TB strains as well as present an European TB research network, TBNET, aimed at advancing science, clinical research, training, policy development and public health.
“TB is a global problem that needs to be dealt with by the international community,” urges Professor Giovanni Battista Migliori, ERS Assembly Head of Respiratory Infections and Director of the WHO Collaborating Centre for TB and Lung Disease, Tradate, Italy.
TBNET is an ERS-supported Clinical Research Collaboration (CRC) in the area of tuberculosis research, working in close collaboration with WHO and ECDC. The main areas of focus are the development of improved diagnostic methods and new drugs as well as the prevention and control of drug-resistant TB.
“One of the biggest problems in most European countries is that treatment success rates are far below the 85% target set by the WHO World Health Assembly, thereby promoting resistance to common anti-tuberculosis drugs” explains Dr Davide Manissero, Head of Section Respiratory Tract Infections and Tuberculosis Programme Coordinator at the ECDC, Stockholm, Sweden.
“Part of the problem is that treatment for multidrug-resistant TB takes substantially longer than for uncomplicated TB; treatment of MDR requires up to 24 months` worth of treatment. The drugs needed are less effective than the first-line drugs for the treatment of drug-susceptible TB and cause more side effects,” says Dr Manissero.For multidrug-resistant TB, the treatment success rate is extremely low (31%).
The M/XDR-TB threat is further aggravated by the poor outcomes of this group of patients. In a cohort of 1,100 patients only 30.9% of those who started treatment in 2006 (2006 cohort) were successfully treated in the EU/EEA. A high percentage (13.2%) of these MDR-TB cases defaulted from treatment, increasing the risk for XDR-TB.
The latest figures on multidrug-resistant tuberculosis show about 440,000 cases of MDR-TB, causing at least 150,000 deaths. XDR-TB has been reported officially from 58 countries as of March 2010, explains Professor Mario Raviglione, Director, Stop TB Department, WHO, Geneva. “Of all cases of TB, over a million occurred among people living with HIV/AIDS and nearly half a million were fatal.”
It is unclear whether HIV infection is a risk factor for drug-resistant or MDR-TB. Known factors that can promote the development of resistance include malabsorption, drug intolerance, drug interactions, and noncompliance among intravenous drug abusers.
Dr Raviglione concludes: “Proper TB control based on early and rapid detection and adequate treatment until cure must be in place everywhere to interrupt transmission, avert deaths, and prevent MDR-TB.”
Dr. Anka Stegmeier-Petroianu | idw
How extreme environmental conditions affect the human brain
05.12.2019 | Max-Planck-Institut für Bildungsforschung
New remote-controlled 'smart' platform helps in cardiovascular disease treatment
05.12.2019 | Chinese Academy of Sciences Headquarters
With ultracold chemistry, researchers get a first look at exactly what happens during a chemical reaction
The coldest chemical reaction in the known universe took place in what appears to be a chaotic mess of lasers. The appearance deceives: Deep within that...
Abnormal scarring is a serious threat resulting in non-healing chronic wounds or fibrosis. Scars form when fibroblasts, a type of cell of connective tissue, reach wounded skin and deposit plugs of extracellular matrix. Until today, the question about the exact anatomical origin of these fibroblasts has not been answered. In order to find potential ways of influencing the scarring process, the team of Dr. Yuval Rinkevich, Group Leader for Regenerative Biology at the Institute of Lung Biology and Disease at Helmholtz Zentrum München, aimed to finally find an answer. As it was already known that all scars derive from a fibroblast lineage expressing the Engrailed-1 gene - a lineage not only present in skin, but also in fascia - the researchers intentionally tried to understand whether or not fascia might be the origin of fibroblasts.
Fibroblasts kit - ready to heal wounds
Research from a leading international expert on the health of the Great Lakes suggests that the growing intensity and scale of pollution from plastics poses serious risks to human health and will continue to have profound consequences on the ecosystem.
In an article published this month in the Journal of Waste Resources and Recycling, Gail Krantzberg, a professor in the Booth School of Engineering Practice...
Conventional light microscopes cannot distinguish structures when they are separated by a distance smaller than, roughly, the wavelength of light. Superresolution microscopy, developed since the 1980s, lifts this limitation, using fluorescent moieties. Scientists at the Max Planck Institute for Polymer Research have now discovered that graphene nano-molecules can be used to improve this microscopy technique. These graphene nano-molecules offer a number of substantial advantages over the materials previously used, making superresolution microscopy even more versatile.
Microscopy is an important investigation method, in physics, biology, medicine, and many other sciences. However, it has one disadvantage: its resolution is...
03.12.2019 | Event News
15.11.2019 | Event News
15.11.2019 | Event News
05.12.2019 | Life Sciences
05.12.2019 | Life Sciences
05.12.2019 | Materials Sciences